Replies to post #9166 on Seelos Therapeutics Inc (SEELQ)

[carlodb1978]

the reason why the Board should be totally renewed is that the last test on Femprox has been done in 2005...incredible, and after 8 years of waste of time for the product, we are now in potentially phase III...an investor is really looking at these aspects, they are not betting like us...

[Tom1950]

If one or two more coverages start at a low ball valuation that is actually a great sign. It means that that we are ready to skyrocket and the street wants the last little bit left before blastoff.

[eicoman]

great points DG

[Dimitrios George]

To be fair, and I am surprised Carlo didn't catch me on this, I did not include and subtract operating costs from Rivkind's peak royalty estimated revenues. If I had done that I probably could have gotten down to $6 per share, but not her $2 price target. But her "peak" estimates are nonsense.

[hentied]

Not sure about your calculation, maybe I am misunderstanding?

APRI has expenses of about $30 mill per year. I doubt that changes once Vitaros starts generating revenues. Maybe those expenses even go higher. $35 mill - $30 mill = $5 mill. earnings (or about 15 cents per share).

I assume we are speaking about the royalties after all licensing has been completed?